It enables the discovery, development and manufacturing of innovative therapeutic products for a wide range of diseases by overcoming the existing obstacles of cell therapy with its high-volume, rapid and inherently safe technology. The MaxCyte GT uses simple, computer-controlled protocols to transfect up to 1 x 1010 cells in less than 30 minutes and is capable of loading multiple molecules (DNA, mRNA, siRNA, proteins, and small molecules) into autologous or allogenic immune, stem/progenitor or somatic cells.
The system is pre-configured with protocols optimized for specific cell types and applications. This cell processing system has received Master File designation with the CBER Division of the U.S. FDA and has been cleared by NIH's RAC and Health Canada.
Features:
Applications: